{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:07:26Z","timestamp":1793765246835,"version":"4.6.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bronchiolitis obliterans syndrome (BOS) is a severe form of chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic cell transplant (HCT), with a 5-year survival rate of 40%. Currently, there is no curative therapy for BOS. Preclinical data suggest that pirfenidone, an antifibrotic drug, may benefit small airway fibrosis in HCT-associated BOS. A single-arm, open-label, 56-week phase 1 trial with 56-month extension evaluated pirfenidone\u2019s tolerability, safety, and efficacy in patients with BOS. Efficacy was measured using pulmonary function tests (PFTs), quantitative computed tomography (qCT) scans, patient-reported outcomes (PROs), cGVHD indices, and laboratory tests. Lung function trajectory was assessed by change in regression slopes before and during treatment. Baseline qCT metrics, including percentage normal lung, air trapping, volume change (Jacobian), and heterogeneity of volume change (Jacobian variance), were analyzed by participant response. Of 30 participants, 25 completed the 56-week trial, and 10 continued into the extension. Overall, 63% tolerated the recommended dose without safety concerns. There was significant improvement in the percent predicted forced expiratory volume in 1 second (P = .00267) when analyzing all participants, and improvement in individual PFT trend for 41.3% of participants. qCT analysis by lobe showed healthier lungs in the upper lobes of responders. Significant improvements were noted in liver function tests, PROs related to physical functioning and shortness of breath, and cGVHD skin indices. These findings indicate that pirfenidone is safe and tolerable in patients with BOS after HCT and may improve lung function and symptoms. Further trials are warranted to evaluate the efficacy of pirfenidone as a treatment for BOS after HCT. This trial was registered at www.ClinicalTrials.gov as #NCT03315741.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016122","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:56:01Z","timestamp":1750769761000},"page":"5024-5037","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2331-3961","authenticated-orcid":false,"given":"Husham","family":"Sharifi","sequence":"first","affiliation":[{"name":"1Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"2Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-1562","authenticated-orcid":false,"given":"Carson Tyler","family":"Moss","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayan","family":"Musa","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of California at Riverside, Riverside, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bell","sequence":"additional","affiliation":[{"name":"4Department of Radiology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-243X","authenticated-orcid":false,"given":"Christian","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9625-168X","authenticated-orcid":false,"given":"Carlos Hernandez","family":"Borges","sequence":"additional","affiliation":[{"name":"1Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"2Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0907-0203","authenticated-orcid":false,"given":"Efthymia Iliana","family":"Matthaiou","sequence":"additional","affiliation":[{"name":"5Department of Immunology, Albany Medical Center, Albany, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[{"name":"6Division of Blood and Marrow Transplantation & Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-7487","authenticated-orcid":false,"given":"Craig J.","family":"Galban","sequence":"additional","affiliation":[{"name":"4Department of Radiology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-0180","authenticated-orcid":false,"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[{"name":"7Division of Internal Medicine, Department of Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Yanik","sequence":"additional","affiliation":[{"name":"8Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-9634","authenticated-orcid":false,"given":"Guang-Shing","family":"Cheng","sequence":"additional","affiliation":[{"name":"9Clinical Research Division, Section of Pulmonary and Critical Care, Fred Hutchinson Cancer Research Center, Seattle, WA"},{"name":"10Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-6504","authenticated-orcid":false,"given":"Joe L.","family":"Hsu","sequence":"additional","affiliation":[{"name":"1Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA"},{"name":"2Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"6","key":"2025101409364607900_bib1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/bmt.2012.241","article-title":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis","volume":"48","author":"Bergeron","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2025101409364607900_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ctr.12638","article-title":"Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Ahn","year":"2015","journal-title":"Clin Transpl"},{"issue":"2","key":"2025101409364607900_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3349\/ymj.2016.57.2.365","article-title":"Risk factor and clinical outcome of bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Rhee","year":"2016","journal-title":"Yonsei Med J"},{"issue":"4","key":"2025101409364607900_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","article-title":"How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"129","author":"Williams","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2025101409364607900_bib5","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1513\/AnnalsATS.201604-262OC","article-title":"Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant","volume":"13","author":"Cheng","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"2025101409364607900_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2025101409364607900_bib7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201410-1818OC","article-title":"Budesonide\/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation","volume":"191","author":"Bergeron","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2025101409364607900_bib8","doi-asserted-by":"crossref","first-page":"2301727","DOI":"10.1183\/13993003.01727-2023","article-title":"ERS\/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults","volume":"63","author":"Bos","year":"2024","journal-title":"Eur Respir J"},{"key":"2025101409364607900_bib9","article-title":"","author":"Administration FaD","year":"2014","journal-title":"Drug approval package \u2014 Esbriet (pirfenidone) capsules"},{"issue":"22","key":"2025101409364607900_bib10","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2014;371(12):1172]","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2025101409364607900_bib11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.healun.2013.02.004","article-title":"Pirfenidone: a potential therapy for progressive lung allograft dysfunction?","volume":"32","author":"Ihle","year":"2013","journal-title":"J Heart Lung Transpl"},{"issue":"18","key":"2025101409364607900_bib12","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","article-title":"Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production","volume":"129","author":"Du","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2025101409364607900_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-022-01716-4","article-title":"The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial","volume":"57","author":"Matthaiou","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2025101409364607900_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2025101409364607900_bib15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"6","key":"2025101409364607900_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00008483-200511000-00011","article-title":"Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire","volume":"25","author":"Kupferberg","year":"2005","journal-title":"J Cardiopulm Rehabil"},{"issue":"8","key":"2025101409364607900_bib17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025101409364607900_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2025101409364607900_bib19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir Med"},{"issue":"13","key":"2025101409364607900_bib20","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.jbiomech.2011.06.009","article-title":"Three-dimensional characterization of regional lung deformation","volume":"44","author":"Amelon","year":"2011","journal-title":"J Biomech"},{"issue":"10","key":"2025101409364607900_bib21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.bbmt.2014.06.014","article-title":"Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"20","author":"Galb\u00e1n","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2025101409364607900_bib22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/nm.2971","article-title":"Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression","volume":"18","author":"Galb\u00e1n","year":"2012","journal-title":"Nat Med"},{"issue":"9","key":"2025101409364607900_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.healun.2024.05.013","article-title":"Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study)","volume":"43","author":"Combs","year":"2024","journal-title":"J Heart Lung Transpl"},{"issue":"4","key":"2025101409364607900_bib24","doi-asserted-by":"crossref","first-page":"00084-2018","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"issue":"3","key":"2025101409364607900_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.bmt.1704561","article-title":"A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation","volume":"34","author":"Hjermstad","year":"2004","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2025101409364607900_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.bmt.1705624","article-title":"Experience of severe fatigue in long-term survivors of stem cell transplantation","volume":"39","author":"Gielissen","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2025101409364607900_bib27","doi-asserted-by":"crossref","first-page":"1853658","DOI":"10.1080\/20018525.2020.1853658","article-title":"Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment","volume":"8","author":"K\u00f8lner-Augustson","year":"2020","journal-title":"Eur Clin Respir J"},{"issue":"5","key":"2025101409364607900_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/bmt.2015.320","article-title":"Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD","volume":"51","author":"Im","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2025101409364607900_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bmt.2016.344","article-title":"Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT","volume":"52","author":"Esser","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2025101409364607900_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/bbmt.2003.49999","article-title":"Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study","volume":"9","author":"Akpek","year":"2003","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2025101409364607900_bib31","doi-asserted-by":"crossref","first-page":"e47024","DOI":"10.1371\/journal.pone.0047024","article-title":"Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials","volume":"7","author":"Jiang","year":"2012","journal-title":"PLoS One"},{"issue":"suppl 1","key":"2025101409364607900_bib32","first-page":"S21","article-title":"Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD)","volume":"7","author":"Matsukuma","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"2025101409364607900_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"2025101409364607900_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12072-020-10069-3","article-title":"Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study","volume":"14","author":"Poo","year":"2020","journal-title":"Hepatol Int"},{"issue":"10","key":"2025101409364607900_bib35","doi-asserted-by":"crossref","first-page":"705.e1","DOI":"10.1016\/j.jtct.2022.07.016","article-title":"Epidemiology of lower respiratory tract infections and community-acquired respiratory viruses in patients with bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective cohort study","volume":"28","author":"Epstein","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2025101409364607900_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1148\/radiol.210363","article-title":"Quantitative CT characteristics of cluster phenotypes in the severe asthma research program cohorts","volume":"304","author":"Trivedi","year":"2022","journal-title":"Radiology"},{"issue":"3","key":"2025101409364607900_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2016.11.053","article-title":"Quantitative computed tomographic imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes","volume":"140","author":"Choi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2025101409364607900_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.chest.2023.12.015","article-title":"Use of quantitative CT imaging to identify bronchial thermoplasty responders","volume":"165","author":"Samant","year":"2024","journal-title":"Chest"},{"issue":"2","key":"2025101409364607900_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.acra.2017.09.014","article-title":"Regional heterogeneity of lobar ventilation in asthma using hyperpolarized helium-3 MRI","volume":"25","author":"Zha","year":"2018","journal-title":"Acad Radiol"},{"issue":"8","key":"2025101409364607900_bib40","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.acra.2015.04.006","article-title":"Ventilation heterogeneity in ex-smokers without airflow limitation","volume":"22","author":"Pike","year":"2015","journal-title":"Acad Radiol"},{"issue":"2 Pt 1","key":"2025101409364607900_bib41","first-page":"646","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2025101409364607900_bib42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1152\/jappl.1964.19.4.713","article-title":"Distribution of blood flow in isolated lung; relation to vascular and alveolar pressures","volume":"19","author":"West","year":"1964","journal-title":"J Appl Physiol"},{"issue":"3","key":"2025101409364607900_bib43","doi-asserted-by":"crossref","first-page":"1900399","DOI":"10.1183\/13993003.00399-2019","article-title":"Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis","volume":"54","author":"Glassberg","year":"2019","journal-title":"Eur Respir J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/5024\/2415156\/blooda_adv-2025-016122-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/5024\/2415156\/blooda_adv-2025-016122-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:40:00Z","timestamp":1760449200000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/5024\/537903\/Pirfenidone-for-the-treatment-of-bronchiolitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":43,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016122","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,10,1]]}}}